Trials / Unknown
UnknownNCT04674488
TILs for Treatment of Metastatic or Recurrent Cervical Cancer
An Exploratory Clinical Study of TILs Treatment for Metastatic or Recurrent Cervical Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Shanghai OriginCell Therapeutics Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, single center, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic cervical carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TILs | a single center, single-arm, open label, interventional study |
Timeline
- Start date
- 2020-12-09
- Primary completion
- 2022-11-09
- Completion
- 2024-11-09
- First posted
- 2020-12-19
- Last updated
- 2020-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04674488. Inclusion in this directory is not an endorsement.